Covid-19 roundup: Kate Bingham to lead UK taskforce; Federal judge to Shkreli: You’re not going to save the world, stay in prison
Europe Could Conditionally Approve Gilead’s Remdesivir In Next Few Days
AstraZeneca Aiming For 30M UK Covid-19 Vaccine Doses By September
3 "Strong Buy" Penny Stocks With Triple-Digit Upside
Biotech’s Golden Moment
Stocks Amid COVID-19 Outbreak: Winners So Far in the Health Industry
Covid-19 roundup: Gilead selects 5 generic manufacturing partners for remdesivir; CanSino outlines PhI/II study in Canada
Pfizer Plans To Test Covid-19 Vaccine On Thousands Of Patients By September- Report
Gilead Signs Remdesivir Licensing Agreements With Five Drugmakers
CEO Albert Bourla On Pfizer’s Involvement With Covid-19
Epic CEO Judy Faulkner on developing new therapies for COVID-19
Moderna CEO Stephane Bancel & Regeneron CEO Leonard Schleifer on a Coronavirus vaccine
DAX attacks 11,000 on COVID-19 treatment hopes - sustainable?
Quidel’s Rapid Covid-19 Antigen Test Scores Emergency FDA Approval
Pfizer Sets Wheels In Motion For Covid-19 Vaccine Production Ramp
Gilead’s Remdesivir Will Be Distributed By State Health Departments
NIH clinical trial tests Remdesivir plus anti-inflammatory drug Baricitinib for COVID-19
NIH kicks off combo study on the impact of Eli Lilly’s Olumiant on Covid-19 cases — using a dose rejected as too dangerous for RA
Moderna Pops 15% On FDA Approval For Phase 2 Covid-19 Vaccine Trial
Beyond Meat Reveals New Summer Strategy, But Analysts See 30% Downside Risk Ahead
Japan Plans To Approve Gilead's Remdesivir Today- Report
AstraZeneca Wins FDA Approval For Diabetes Drug to Treat Heart Failure
Incyte Reports Strong Jakafi Sales, But Recent Rally Sparks Downgrades
Gilead in Talks to Ramp Up Global Supply of Remdesivir Production
Drugmaker Eli Lilly Partners With China’s Junshi For Covid-19 Antibody Treatment
JPMorgan's Bullish Stance on Gilead Sciences (GILD) Stock Comes to an End
Drugmaker AbbVie Reiterates 2020 Guidance, Beats Quarterly Sales
DAX attacks 11,000 on COVID-19 cure hopes - sustainable?
UPDATED: FDA cheers on Gilead's remdesivir with a snap emergency OK, giving biopharma a shot at redemption
Gilead Says Remdesivir Will Be Available To Patients This Week